Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

This study has been terminated.
(Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.)
Sponsor:
Collaborator:
Pfizer
Information provided by:
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00754052
First received: September 15, 2008
Last updated: December 10, 2008
Last verified: December 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: April 2009
  Estimated Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)